GlassScriptPhysician profile
Ryan Geffin
NPI 1013599323
$2,223.02
in general payments reported to CMS, 2019-2025
11 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $353 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,223.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $901.25 | 2024-2025 | Azure Xt Dr Mri Surescan, Micra, Capsurefix Novus Mri Surescan |
| Biosense Webster, INC. | $428.58 | 2025 | Carto 3 |
| Abbott Laboratories | $340.10 | 2025 | Aveir, Gallant |
| Boston Scientific Corporation | $293.37 | 2024-2025 | General - Therapies, Latitude Communicator Power Supply, Watchman Flx |
| Kestra Medical Technology Services, INC. | $99.19 | 2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $35.38 | 2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.23 | 2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $28.54 | 2024 | |
| Amgen INC. | $23.49 | 2025 | Repatha |
| Atricure, INC. | $22.93 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| E.R. Squibb & Sons, L.L.C. | $18.96 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Geffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.